Inventor · disambiguated record
Kevin M. Guckian
Also filed as: GUCKIAN KEVIN · GUCKIAN KEVIN M
38 granted patents·16 pending applications·196 citations·filing 2005–2024
97Inventor score
Top patents by PatentIndex Score
54 records- 0192US10166250B2Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2017·Granted Jan 1, 2019·9 cites·11 claims
- 0292US9572824B2Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2015·Granted Feb 21, 2017·10 cites·14 claims
- 0392US8802659B2Bicyclic aryl sphingosine 1-phosphate analogsTHOMAS JERMAINE·Filed 2010·Granted Aug 12, 2014·20 cites·24 claims
- 0491US9827258B2Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2017·Granted Nov 28, 2017·8 cites·10 claims
- 0591US9186367B2Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2014·Granted Nov 17, 2015·15 cites·14 claims
- 0691US8293923B2Indazole derivatives as modulators of interleukin-1 receptor-associated kinaseGUCKIAN KEVIN·Filed 2007·Granted Oct 23, 2012·52 cites·27 claims
- 0789US8778977B2Pyridinonyl PDK1 inhibitorsLIND KENNETH EGNARD·Filed 2007·Granted Jul 15, 2014·21 cites·15 claims
- 0886US9550798B2Compounds that are S1P modulating agents and/or ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Jan 24, 2017·8 cites·25 claims
- 0985US9555050B2ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Jan 31, 2017·4 cites·24 claims
- 1084US9850206B2S1P and/or ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Dec 26, 2017·4 cites·22 claims
- 1184US9340527B2S1P modulating agentsTHOMAS JERMAINE·Filed 2012·Granted May 17, 2016·6 cites·38 claims
- 1284US9181191B2Heterobicyclic sphingosine 1-phosphate analogsBIOGEN IDEC INC·Filed 2012·Granted Nov 10, 2015·3 cites·38 claims
- 1384US2024294524A1Heterocyclic compounds useful as pdk1 inhibitorsVIRACTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1482US10246456B2IRAK4 inhibiting agentsBIOGEN MA INC·Filed 2015·Granted Apr 2, 2019·5 cites·4 claims
- 1582US9522889B2ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Dec 20, 2016·5 cites·31 claims
- 1682US8349849B2Heterobicyclic sphingosine 1-phosphate analogsBIOGEN IDEC INC·Filed 2009·Granted Jan 8, 2013·6 cites·21 claims
- 1781US10034869B2S1P modulating agentsBIOGEN MA INC·Filed 2017·Granted Jul 31, 2018·2 cites·18 claims
- 1880US12275728B2O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitorsBIOGEN MA INC·Filed 2024·Granted Apr 15, 2025·0 cites·2 claims
- 1980US10030016B2Heterocyclic compounds useful as PDK1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2015·Granted Jul 24, 2018·2 cites·16 claims
- 2080US9808449B2S1P modulating agentsBIOGEN MA INC·Filed 2015·Granted Nov 7, 2017·2 cites·21 claims
- 2179US9499485B2Compounds that are S1P modulating agents and/or ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Nov 22, 2016·4 cites·14 claims
- 2277US8546359B2Bicyclic aryl sphingosine 1-phosphate analogsCaldwell richard d·Filed 2012·Granted Oct 1, 2013·4 cites·31 claims
- 2377US2023113598A1Heterocyclic compounds useful as pdk1 inhibitorsVIRACTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2476US10894040B2S1P modulating agentsBIOGEN MA INC·Filed 2019·Granted Jan 19, 2021·0 cites·20 claims
- 2574US8269043B2Bicyclic aryl sphingosine 1-phosphate analogsCaldwell richard d·Filed 2009·Granted Sep 18, 2012·2 cites·19 claims
- 2673US10577367B2IRAK4 inhibiting agentsBIOGEN MA INC·Filed 2019·Granted Mar 3, 2020·1 cites·6 claims
- 2770US9546165B2Heterocyclic compounds useful as PDK1 inhibitorsARNDT JOSEPH·Filed 2010·Granted Jan 17, 2017·2 cites·12 claims
- 2870US2021070752A1Heterocyclic compounds useful as pdk1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2968US9765016B2S1P modulating agentsBIOGEN MA INC·Filed 2014·Granted Sep 19, 2017·1 cites·18 claims
- 3066US2019209592A1Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2018·Application pending·0 cites
- 3165US10406144B2SIP modulating agentsBIOGEN MA INC·Filed 2018·Granted Sep 10, 2019·0 cites·18 claims
- 3263US2019119268A1Heterocyclic compounds useful as pdk1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3362US9873693B2Methods of treatment using pyridinonyl PDK1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2014·Granted Jan 23, 2018·0 cites·15 claims
- 3460US10081646B2Heterobicyclic sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2017·Granted Sep 25, 2018·0 cites·26 claims
- 3560US2018370966A1Methods of treatment using pyridinonyl pdk1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3660US2025304577A1Tyk2 inhibitorsBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 3758US2025018046A1Compounds for targeting degradation of irak4 proteinsBIOGEN MA INC·Filed 2022·Application pending·0 cites
- 3857US12180205B2O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitorsBIOGEN MA INC·Filed 2019·Granted Dec 31, 2024·0 cites·20 claims
- 3957US2023117898A1O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitorsBIOGEN MA INC·Filed 2022·Application pending·0 cites
- 4056US2024343733A1Compounds for targeting degradation of irak4 proteinsBIOGEN MA INC·Filed 2022·Application pending·0 cites
- 4156US2024287076A1Compounds for targeting degradation of bruton's tyrosine kinaseBIOGEN MA INC·Filed 2022·Application pending·0 cites
- 4255US9708353B2Heterobicyclic sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2015·Granted Jul 18, 2017·0 cites·29 claims
- 4350US12421224B2Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitorsBIOGEN MA INC·Filed 2020·Granted Sep 23, 2025·0 cites·20 claims
- 4449US2010035918A1Imidazolone Compounds and Methods of Making and Using the SameBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 4548US11459324B2O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitorsBIOGEN MA INC·Filed 2019·Granted Oct 4, 2022·0 cites·21 claims
- 4648US9944666B2Compounds that are S1P modulating agents and/or ATX modulating agentsBIOGEN MA INC·Filed 2016·Granted Apr 17, 2018·0 cites·15 claims
- 4748US2010056505A1Substituted PyrazalonesBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 4847US10017506B2ATX modulating agentsBIOGEN MA INC·Filed 2016·Granted Jul 10, 2018·0 cites·21 claims
- 4946US12319679B2Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitorsBIOGEN MA INC·Filed 2019·Granted Jun 3, 2025·0 cites·18 claims
- 5045US10273234B2Compounds that are S1P modulating agents and/or ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Apr 30, 2019·0 cites·14 claims
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Kevin M. Guckian files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →